Masahiko Noguchi

Masahiko Noguchi

Auto-generated profile, based on publicly available information

Masahiko Noguchi

Department of Cardiology, Tokyo Bay Urayasu Ichikawa Medical Center, Urayasu, Japan

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2022 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
ZCZhaoyang Chen
Zhaoyang Chen
MMMitsuaki Matsumura
Mitsuaki Matsumura
GMGary S. Mintz
Gary S. Mintz
MNMasahiko Noguchi
Masahiko Noguchi
TFTatsuhiro Fujimura
Tatsuhiro Fujimura
AMAkiko Maehara
Akiko Maehara
Background: Clinical and morphological factors associated with lipidic versus calcified neoatherosclerosis within second-generation drug-eluting stents and the impact of lipidic versus calcified neoatherosclerosis on long-term outcomes after repeat intervention have not been well studied. Methods: A total of 512 patients undergoing optical coherence tomography before percutaneous coronary intervention for second-generation drug-eluting stents in-stent restenosis were included. Neoatherosclerosis was defined as lipidic or calcified neointimal hyperplasia in ≥3 consecutive frames or ruptured lipidic neointimal hyperplasia. The primary outcome was target lesion failure (cardiac death, target vessel myocardial infarction, definite stent thrombosis, or clinically driven target lesion revascularization). Results: The overall prevalence of neoatherosclerosis was 28.5% (146/512): 56.8% lipidic, 30.8% calcified, and 12.3% both lipidic and calcific. The prevalence increased as a function of time from stent implantation: 20% at 1 to 3 years, 30% at 3 to 7 years, and 75% >7 years. Renal insufficiency, poor lipid profile, and time from stent implantation were associated with lipidic neoatherosclerosis, whereas severe renal insufficiency, female sex, and time from stent implantation were associated with calcified neoatherosclerosis. Multivariable Cox regression revealed that female sex and lipidic neoatherosclerosis were associated with more target lesion failure, whereas stent age and final minimum lumen diameter after reintervention were related to lower target lesion failure. Calcified neoatherosclerosis was not related to adverse events after reintervention for in-stent restenosis given a large enough minimum lumen diameter was achieved. Conclusions: Lipidic but not calcified neoatherosclerosis was associated with poor subsequent outcomes after repeat revascularization if optimal stent expansion was achieved in lesions with calcified neoatherosclerosis.

7 March 2025 in Journal of Cardiology
Verified
Journal Article
Closed access
MNMasahiko Noguchi
Masahiko Noguchi
TDTomotaka Dohi
Tomotaka Dohi

25 April 2020 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
MNMasahiko Noguchi
Masahiko Noguchi
MTMinoru Tabata
Minoru Tabata
KOKotaro Obunai
Kotaro Obunai
KSKentaro Shibayama
Kentaro Shibayama
JIJoji Ito
Joji Ito
KHKentaro Hayashida
Kentaro Hayashida

6 August 2021 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Open access
PDF file
MNMasahiko Noguchi
Masahiko Noguchi
TDTomotaka Dohi
Tomotaka Dohi
SOShinya Okazaki
Shinya Okazaki
MMMitsuaki Matsumura
Mitsuaki Matsumura
MTMitsuhiro Takeuchi
Mitsuhiro Takeuchi
AMAkiko Maehara
Akiko Maehara
Objectives: This study was conducted to use optical coherence tomography (OCT) to compare vascular healing between bioresorbable polymer (BP) and durable polymer (DP) everolimus‐eluting stents (EES) in patients with acute coronary syndromes (ACS).Background: Whether BP‐EES induce better vascular healing compared to contemporary DP‐EES remains controversial, especially for ACS.Methods: In this prospective, randomized, non‐inferiority trial, we used OCT to compare 6‐month vascular healing in patients with ACS randomized to BP versus DP‐EES: percent strut coverage (primary endpoint, non‐inferiority margin of 2.0%) and neointimal thickness and percent neointimal hyperplasia (NIH) volume. As an exploratory analysis, morphological factors related to the endpoints and the effect of underlying lipidic plaque on stent healing were evaluated.Results: A total of 104 patients with ACS were randomly assigned to BP‐EES (n = 52) versus DP‐EES (n = 52). Of these, 86 patients (40 BP‐EES and 46 DP‐EES) were included in the final OCT analyses. Six‐month percent strut coverage of BP‐EES (83.6 ± 11.4%) was not non‐inferior compared to those of DP‐EES (81.6 ± 13.9%), difference 2.0% (lower 95% confidence interval‐2.6%), pnon‐inferiority = 0.07. There were no differences in neointimal thickness 70.0 ± 33.9 μm versus 67.2 ± 33.9 μm, p = 0.71; and percent NIH volume 7.5 ± 4.7% versus 7.3 ± 5.3%, p = 0.85. By multivariable linear regression analysis, stent type was not associated with percent strut coverage or percent NIH volume; however, percent baseline embedded struts or stent expansion was positively associated with percent NIH volume. Greater NIH volume was observed in lipidic compared with non‐lipidic segments (8.7 ± 5.6% vs. 6.1 ± 5.2%, p = 0.005).Conclusions: Six‐month strut coverage of BP‐EES was not non‐inferior compared to those of DP‐EES in ACS patients. Good stent apposition and expansion were independently associated with better vascular healing.

14 April 2022 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
HSHanan Salem
Hanan Salem
GMGary S. Mintz
Gary S. Mintz
MMMitsuaki Matsumura
Mitsuaki Matsumura
MZMingyou Zhang
Mingyou Zhang
EUEisuke Usui
Eisuke Usui
AMAkiko Maehara
Akiko Maehara

27 February 2024 in Open Heart
Verified
Journal Article
Open access
PDF file
MNMasahiko Noguchi
Masahiko Noguchi
MTMinoru Tabata
Minoru Tabata
JIJoji Ito
Joji Ito
NKNahoko Kato
Nahoko Kato
KOKotaro Obunai
Kotaro Obunai
KHKentaro Hayashida
Kentaro Hayashida
Objectives The clinical outcomes of transcatheter aortic valve replacement (TAVR) in patients with aortic stenosis (AS) and concomitant active cancer remain insufficiently explored. This study aimed to assess the midterm outcomes of TAVR in patients diagnosed with AS and active cancer. Methods Data from the OCEAN-TAVI, a prospective Japanese registry of TAVR procedures, was analysed to compare prognoses and clinical outcomes in patients with and without active cancer at the time of TAVR. Results Of the 2336 patients who underwent TAVR from October 2013 to July 2017, 89 patients (3.8%) had active cancer, whereas 2247 did not. Among patients with active cancer, 49 had limited-stage cancer (stage 1 or 2). The prevalent cancers identified before TAVR were colon (21%), prostate (18%), lung (15%), liver (11%) and breast (9%). Although the periprocedural complications and 30-day mortality rates were comparable between the groups, the 3-year survival rate after TAVR was notably lower in patients with active cancer (64.7%) than in those without active cancer (74.7%; p=0.016). Nevertheless, the 3-year survival rate of patients with limited-stage cancer (stage 1 or 2) did not significantly differ from those without cancer (70.6% vs 74.7%, p=0.50). Conclusions The patients with active cancer exhibited significantly reduced midterm survival rates. However, no distinct disparity existed in those with limited-stage cancer (stage 1 or 2). Although TAVR is a viable treatment in patients with AS with active cancer, the type and stage of cancer and prognosis should be carefully weighed in the decision-making process.